Activity of Plazomicin Tested against

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

1. Antimicrobial resistance in paediatric bloodstream infections in Tanzania: a longitudinal comparison of two cohort studies.BMC microbiology · 2026
   Article
2. Precision Approaches to Carbapenem-Resistant Infections in the ICU: Integrating Diagnostics, Stewardship, and Novel Therapies.Diagnostics (Basel, Switzerland) · 2026
   Review
3. Performance evaluation of plazomicin susceptibility testing of Enterobacterales on VITEK 2 and VITEK 2 Compact Systems.Journal of clinical microbiology · 2025
   Article
4. Emergence of Carbapenem-ResistantPathogens (Basel, Switzerland) · 2025
   Article
5. In vitro activity of plazomicin and other aminoglycosides against Klebsiella pneumoniae multidrug-resistant strains.The Journal of antibiotics · 2024
   Article
6. Evaluation of theFrontiers in microbiology · 2024
   Article
7. Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers.Open forum infectious diseases · 2023
   Article
8. Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023
   Review
9. New antibiotics for Gram-negative pneumonia.European respiratory review : an official journal of the European Respiratory Society · 2022
   Review
10. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
11. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.Infection · 2022
    Article
12. Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.Drugs · 2022
    Review
13. Multicenter Clinical Evaluation of ETEST Plazomicin (PLZ) for Susceptibility Testing of Enterobacterales.Journal of clinical microbiology · 2022
    Article
14. Present and Future Perspectives on Therapeutic Options for Carbapenemase-ProducingMicroorganisms · 2021
    Review
15. An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria.Journal of clinical medicine · 2021
    Review
16. Plazomicin in multidrug-resistant complicated urinary tract infections: a scoping review.Therapeutic advances in infectious disease
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as